Ovarian cancer vaccine shows promise in early safety trial
NCT ID NCT02111941
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This early-phase study tested a personalized vaccine made from patients' own white blood cells to treat advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine was designed to help the immune system recognize and attack cancer cells. The main goal was to check safety and see if the vaccine triggers an immune response. Nineteen patients who had already undergone surgery and chemotherapy took part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SEROMUCINOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.